Drug‐Drug Interaction of Letermovir and Atorvastatin in Healthy Participants
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1071
Abstract: Letermovir (MK‐8228/AIC246) is a cytomegalovirus (CMV) DNA terminase complex inhibitor for CMV prophylaxis in adult patients undergoing hematopoietic stem cell transplant. It is cytochrome P450 (CYP) 3A inhibitor and inhibits organic anion transporting polypeptide 1B1/3… read more here.
Keywords: atv cmax; coadministration; drug drug; letermovir ... See more keywords
Efficacy and Pharmacoeconomic Impact of Letermovir for CMV Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.349
Abstract: Cytomegalovirus (CMV) seropositivity and early CMV reactivation after hematopoietic-cell transplantation (HCT) remain associated with increased mortality. Those at high risk include CMV seropositive recipient/donor pairs (CMV R+ or D+) and those on escalated immunosuppression (prednisone… read more here.
Keywords: reactivation; cmv reactivation; cmv; hct ... See more keywords
Letermovir for Secondary Cytomegalovirus (CMV) Prophylaxis in a Pediatric Stem Cell Transplant Patient
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.354
Abstract: Patients who undergo stem cell transplants are at a significant risk of infections. Cytomegalovirus (CMV) is an organism of particular concern in this population. Current treatments options for CMV include ganciclovir, valganciclovir, foscarnet, and cidofovir.… read more here.
Keywords: patient; cmv; cmv viral; viral load ... See more keywords
Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2020.1843321
Abstract: Abstract Background The cost-effectiveness of letermovir as cytomegalovirus (CMV) prophylaxis in adult seropositive patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), compared with the conventional strategy of preemptive treatment, has not been evaluated in Asia.… read more here.
Keywords: hong kong; cost; prophylaxis; letermovir ... See more keywords
Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency
Sign Up to like & getrecommendations! Published in 2019 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofz375
Abstract: Abstract Background Letermovir is a novel cytomegalovirus antiviral that is approved for prophylaxis in hematopoietic stem cell transplantation recipients Methods After obtaining informed consent, letermovir prophylaxis was started in a patient with a presumed late-onset… read more here.
Keywords: immunodeficiency; resistant cytomegalovirus; letermovir resistant; letermovir ... See more keywords
Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation
Sign Up to like & getrecommendations! Published in 2018 at "Current Opinion in Infectious Diseases"
DOI: 10.1097/qco.0000000000000459
Abstract: Purpose of review Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral… read more here.
Keywords: infection; hsct; allogeneic haematopoietic; letermovir ... See more keywords
Letermovir for cytomegalovirus prophylaxis in high‐risk heart transplant recipients
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Transplantation"
DOI: 10.1111/ctr.14808
Abstract: Letermovir is a novel agent for the prevention of cytomegalovirus (CMV) infection and disease that, unlike traditional CMV DNA polymerase inhibitors, does not carry the risk of myelosuppression. The purpose of this study was to… read more here.
Keywords: heart transplant; high risk; risk; letermovir ... See more keywords
Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological-based pharmacokinetic modeling.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and translational science"
DOI: 10.1111/cts.13509
Abstract: Letermovir is approved for use in cytomegalovirus-seropositive hematopoietic stem cell transplant recipients and is investigated in other transplant settings. Nonlinear pharmacokinetics (PKs) were observed in clinical studies after intravenous and oral dosing across a wide… read more here.
Keywords: everolimus; nonlinear pharmacokinetics; drug interaction; letermovir ... See more keywords
Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation
Sign Up to like & getrecommendations! Published in 2022 at "Transplant Infectious Disease"
DOI: 10.1111/tid.13904
Abstract: Letermovir has been approved as a novel cytomegalovirus (CMV) prophylactic agent after allogeneic hematopoietic stem cell transplantation (HSCT). However, there are still insufficient data to properly evaluate the real‐world role of letermovir, and the risk… read more here.
Keywords: allogeneic hematopoietic; stem cell; cytomegalovirus; cell transplantation ... See more keywords
Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00657-22
Abstract: With balanced safety-efficacy profile, letermovir anti-cytomegalovirus (CMV) prophylaxis is used in hematopoietic stem cell transplant recipients (HSCTR). We assessed feasibility and usefulness of letermovir therapeutic drug monitoring (TDM) in HSCTR. ABSTRACT With balanced safety-efficacy profile,… read more here.
Keywords: stem cell; letermovir ctrough; hematopoietic stem; letermovir ... See more keywords
New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by In Vitro Exposure to Letermovir and Ganciclovir
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00922-18
Abstract: Letermovir is a human cytomegalovirus (CMV) terminase inhibitor recently approved as prophylaxis in stem cell transplant recipients. In further studies of emerging drug resistance, a baseline laboratory CMV strain was serially propagated in cell culture… read more here.
Keywords: drug resistance; human cytomegalovirus; resistance; letermovir ... See more keywords